Factors Associated with Hepatitis B Vaccine Response Among Dentists

Abstract

The objective of this study was to evaluate personal and immunization factors associated with serologic evidence of hepatitis B virus (HBV) vaccine response. A study was conducted using data from United States dentists participating from 1987 to 1991 in the Health Screening Program of the American Dental Association's annual session. This study included dentists (n = 507) who (1) received their most recent dose of HBV vaccine within the previous 10 months, (2) completed a core questionnaire, and (3) were tested for HBV markers (HBsAg, anti-HBs, and anti-HBc) and were found not to have evidence of past or present infection. Non-responders were defined as dentists testing negative for all three markers (n = 100). Responders were defined as dentists having serological evidence of anti-HBs alone (n = 407). Logistic regression models were used to assess the relationship of vaccine response to the variables sex, age, number of vaccine doses, site of vaccination, type of vaccine, and history of hepatitis. Vaccine response was most strongly associated with sex, age, and number of doses. Factors unrelated to vaccine response included type of vaccine and history of hepatitis. Adherence to the recommended number of doses and early vaccination are critical to adequate protection against hepatitis B infection of dentists, who are often exposed to blood and other body fluids.

Keywords

Antibodies Dentists Hepatitis B Immunity Vaccine.

Get full access to this article

View all access options for this article.

References

Alter MJ , Hadler SC , Margolis HS , Alexander WJ , Pin Ya Hu , Judson FN , et al.(1990). The changing epidemiology of hepatitis B in the United States: need for alternative vaccination strategies. JAMA 263:1218-1222.

Andre F. (1989). Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 87(Suppl 3A):14-20.

CDC (1985). Suboptimal response to hepatitis B vaccine given by injection into the buttock. MMWR 34:105-113.

CDC (1989). Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR 38(No.S-6):5-15.

CDC (1990). Protection against viral hepatitis; Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 39:5-22.

CDC (1991). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 40(RR-13):1-25.

Dienstag JL , Werner BG , Polk BF , Snydman DR , Craven DE , Platt R. , et al. (1984). Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 101:34-40.

Gruninger SE , Siew C. , Chang SB , Clayton R. , Kuo G. , Verrusio AC , et al. (1991). Hepatitis B, C, and HIV infection among dentists (abstract). J Dent Res 70:532.

Hadler SC , Frances DP , Maynard JE , Thompson SE , Judson FN , Echenberg DF , et al. (1986). Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N EngJ Med 315:209-214.

10.

Hadler SC , Margolis HS (1992). Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. In: Current clinical topics in infectious diseases. Remington JS , Swartz MN , editors. Boston: Blackwell Scientific Publications, pp. 283-308.

11.

Jilg W. , Schmidt M. , Deinhardt F. (1988). Persistence of specific antibodies after hepatitis B vaccination.J Hepatol 6:201-207.

12.

Kleinbaum GK , Kupper LL , Morgenstern H , editors ( 1982). Epidemiologic research. New York, NY: Van Nostrand Reinhold, pp. 419-446.

13.

Perrillo RP , Bodicky CJ , Campbell CR , Davis E. , Veit H. ( 1988). Randomized, controlled study of a recombinant yeast hepatitis B vaccine in the mentally retarded. In: Viral hepatitis and liver disease. Zuckerman AJ , editor. New York: Alan R. Liss, Inc., pp. 1062-1064.

14.

Shaw FE , Guess HA , Roets JM , Mohr FE , Coleman PJ , Mandel EJ , et al. (1989). Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 7:425-430.

15.

Siew C. , Gruninger SE , Mitchell EW , Burrell KH (1987). Survey of hepatitis B exposure and vaccination in volunteer dentists. JADA 114:457-459.

16.

Szmuness W. , Stevens CE , Harley EJ , Zang EA , Oleszko WR , William DC , et al. (1980). Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States . N Engl J Med 303:833-841.

17.

Szmuness W. , Stevens CE , Harley EJ , Zang EA , Alter HJ , Taylor PE , et al. (1982). Hepatitis B vaccine in medical staff of hemodialysis units. N Engl J Med 307:1481-1486.

18.

Wainwright RB , McMahon BJ , Bulkow LR , Parkinson AJ , Harpster AP , Hadler SC (1989). Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 261:2362-2366.

19.

Weber DJ , Rutala WA , Samsa GP , Santimaw JE , Lemon SM (1985). Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 254:3187-3189.

20.

West DJ , Snavely DB , Zajac BA , Brown GW , Babb CJ ( 1990). Development and persistence of antibody in a high risk institutionalized population given plasma-derived hepatitis B vaccine. Vaccine 8:111-114.

21.

Zajac BA , West DJ , McAleer WJ , Scolnick EM (1986). Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 13(Suppl A):39-45.